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The increasing rate of implantable cardioverter defibrillator (ICD) implantation coupled
with shared risk factors between lung cancer and ischemic cardiac disease means that
the need for radiotherapy in cardiac device patients is set to become commonplace. We
describe two cases referred to our electrophysiology service over a 6-month period. Both
had been diagnosed with lung cancer in tissue directly posterior to a previously
implanted ICD device. The cases highlight the risks to device function caused by ionizing
radiation, the practical difficulties and ethical dilemmas of delivering radiotherapy to
cardiac device patients safely and a novel setting for the use of a wearable defibrillator
system.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
The increasing rate of implantable cardioverter defibrillator
(ICD) implantation coupled with shared risk factors between
lung cancer and ischemic cardiac diseasemeans that the need
for radiotherapy in cardiac device patients is set to become
commonplace. We describe two cases referred to our elec-
trophysiology service over a 6-month period. Both had been
diagnosed with lung cancer in tissue directly posterior to a
previously implanted ICD device. The cases highlight the risks
to device function caused by ionizing radiation, the practical
difficulties and ethical dilemmas of delivering radiotherapy to
cardiac device patients safely and a novel setting for the use of
a wearable defibrillator system..uk (R.W. Bowers).
2013, Cardiological Societ2. Case reports and discussion
Our first case had a biventricular pacemaker with defibrillator
capability (D234TRK Consulta, Medtronic, Minnesota, USA)
implanted for Mobitz Type 2 second-degree heart block on a
background of severe, ischemic cardiomyopathy. Case 2 had a
secondary prevention, dual chamber ICD (T167 Vitality 2 EL,
Guidant, Massachusetts, USA) implanted after an episode of
ventricular tachycardia.
For both patients, stage three squamous-cell lung cancer
was diagnosed by local Respiratory Physicians and Positron
Emission Tomography e Computed Tomography imaging
clearly demonstrated the tumors lying directly posterior to the
cardiac devices (Figs. 1 and 2).y of India. All rights reserved.
Fig. 1 e Imaging for Case 1. Plain film radiography of the chest at the time of device implant (A) and at presentation to the
respiratory team (B), a new opacity is clearly seen. Positron Emission Tomography e Computerized Tomography imaging of
the lung mass in transverse (C) and sagittal (D) planes demonstrating relationship to cardiac device.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 1 1 1e1 1 4112Advice from the Oncology Multi-Disciplinary Team was
that, treated with radical chemo-radiotherapy, the median
two-year survival was approximately 30%, with a proportion
of patients cured of their cancer. With palliative chemo-
therapy alone the prognosis was significantly worse. The pa-
tients were referred to our service to advise on the safety of
delivering radiotherapy with an ICD in situ, and to consider
strategies to facilitate cancer treatment. The radiotherapy
courses were to be 55 Gray (Gy), delivered in 20 fractions.
Consensus guidance on the management of cardiac device
patients requiring radiotherapy was limited to a 1994 publica-
tion by the American Association of Physicists in Medicine.1 It
dealt exclusively with bradycardia devices, and recommended
a maximum cumulative dose to a device of no more than 2 Gy.
In 1997, last published a review including a description of
the complementary metal oxide semiconductor (CMOS)
technology used in modern cardiac devices.2 He documents
increased potential for radiation induced malfunction
compared to older, bipolar semi-conductor technology. CMOS
circuits use silicon as a semiconductor and silicon dioxide as
an insulator. Whilst ionizing radiation effects tend to be
transient in the semiconductor, in the silicon dioxideinsulator accumulation of positive charge carriers can lead to
the formation of aberrant electrical pathways and to device
malfunction. Last’s review concludes that “there does not
appear to be any consistent way to predict how a device will
fail or at what dose failure will occur”.
Current experimental evidence supports this variation in
resilience to ionizing radiation as characteristic of high-
energy devices also. Hurkmans et al3 irradiated new ICDs.
Included in the study were 5 identical devices, of which 1
malfunctioned at a cumulative dose of less than 0.5 Gy whilst
another was functioning up to 120 Gy.
Given the possibility of cure offered by radical chemo-
radiotherapy, the limitations to such treatment created by
an overlying device and the concern expressed in the litera-
ture regarding device malfunction during radiation exposure,
we advised removal of the pulse generators in order to safely
deliver radiotherapy to the underlying cancer. The leads
remained in situ.
A permanent ventricular pacemaker implanted on the
contralateral side to the cancer provided interim pacing sup-
port for the pacemaker-dependent first case. This was
explanted at ICD re-implantation.
Fig. 2 e Imaging for Case 2. Plain film radiography of the chest at the time of presentation to the respiratory team (A), an
opacity is seen between the cardiac silhouette and the device. Positron Emission Tomography e Computerized Tomography
imaging of the lung mass in coronal (B) and sagittal (C) planes demonstrating relationship to cardiac device.
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 1 1 1e1 1 4 113Our strategy raised two specific issues regarding the
continued provision of protection from Sudden Cardiac Death
(SCD) in patients known to be at significantly increased risk of
non cardiac mortality due to their cancer. First, whether to re-
implant pulse generators after radiotherapy? Second, if device
reimplantation were planned, how to provide interim SCD
protection?
There is no specific guidance on the ethics of reimplantation
in patients requiring device explantation. International guide-
lines suggest ICD therapy is suitable for patients “who have a
reasonable expectationof survivalwitha good functional status
formore than 1 year”.4We felt thiswas applicable to both cases
basedon theestimatesgivenby theOncologists. Followinga full
and frank discussion, both patients elected to undergo device
reimplantation after radiotherapy.
The issue of interim protection from SCD was discussed
with both patients prior to explantation. We elected to offer
temporary protection using a wearable defibrillator jacket
worn under clothing in direct skin contact. The “Zoll Life-
vest” wearable defibrillator system (ZOLL Medical Corpora-
tion, Pittsburgh, USA) is able to monitor cardiac rhythm and
deliver automated shocks if ventricular fibrillation is detected.
The use of wearable defibrillator jackets has been described in
groups with transient high risk of malignant ventricular
arrhythmia.5 It is also recommended as bridging therapy in
patients requiring temporary removal of an infected implan-
ted defibrillator by American and European Guidelines.4At completion of radiotherapy treatment, when radiation
induced inflammation was sufficiently resolved, a new
generator was implanted onto the chronic leads. It was noted
that the tissues were fibrous and reimplantation required
careful surgical technique.
Subsequent to our management of these cases, The Dutch
Society of Radiotherapy and Oncology published new guid-
ance on the management of radiation oncology patients
with a pacemaker or ICD.6 Both cases would be considered
“high risk” by their assessment and the guidance advises to
“reconsider radiotherapy” and only “in exceptional cases a
decision to start radiotherapy can be made”. Relocation of the
cardiac device is mentioned, but without description of how
this would be achieved whilst minimizing procedural risk and
yet facilitating relocation to a site considered to receive a
lower radiation dose.3. Conclusion
Our strategy of temporary pulse generator removal allowed
both patients to undergo a full course of potentially curative
radiotherapy. To our knowledge, this is the first description of
a wearable defibrillator system being used to facilitate tem-
porary removal of an ICD for radiotherapy to be safely deliv-
ered. It offers an attractive solution to a clinical problem that,
with increasing numbers of complex devices being implanted
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 1 1 1e1 1 4114worldwide and considerable overlap in risk factors for lung
malignancy and cardiac disease, is likely to be seen more
frequently.Conflicts of interest
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